DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Chronic Low Back Pain

Information source: Unipharm, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Low Back Pain

Intervention: ARTRA (Dietary Supplement)

Phase: N/A

Status: Completed

Sponsored by: Unipharm, Inc.

Official(s) and/or principal investigator(s):
Gurkirpal Singh, MD, Study Chair, Affiliation: Irish Clinical Outcomes in Research and Education

Summary

To study the safety and efficacy of ARTRA (glucosamine chondroitin sulfate) in the treatment of non-specific low-back pain of lumbosacral localization in ambulatory care.

Clinical Details

Official title: Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Non-specific Chronic Low Back Pain of Lumbosacral Localization in Ambulatory Care

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Pain Intensity

Secondary outcome:

Oswestry Disability Index

Patient global assessment of efficacy

NSAID consumption

Detailed description: We enrolled patients between 40 and 65 years of age who had low back pain for at least 12 weeks with a pain intensity >3 on a 0-10 point visual analogue scale (VAS). Major exclusion criteria were presence of fibromyalgia, degenerative spondylolisthesis, and alcohol and/or drug abuse. All patients were treated with ARTRA (combination of glucosamine hydrochloride 500 mg and chondroitin sulfate 500 mg in tab; Unipharm Inc.) at a dose of 1 tab bid for the first month and then 1 tab daily for the next two months. The primary endpoint was pain intensity (at rest and movement) as measured on a 0-10 point VAS. Secondary endpoints included Oswestry Disability Index, patient global assessment of efficacy (0-5 scale) and NSAID consumption.

Eligibility

Minimum age: 40 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Patients aged 40-65 years, inclusively. 2. Pain intensity according to Visual Analogue Scale (VAS) > 3 points. 3. Duration of back pain > 12 weeks. 4. Pain reinforcement during movement in lumbar spine. 5. Osteoarthritis, spondylarthrosis, osteochondrosis. 6. Given written Informed consent form for participation in the study. 7. Treatment with ARTRA Exclusion Criteria: 1. History of allergic reactions to chondroprotectors. 2. Participation in another clinical study within 30 days before screening or during this study. 3. Fibromyalgia. 4. Active neoplastic disease, history of neoplastic disease within 3 years before screening. 5. Paget's disease. 6. Degenerative spondylolisthesis. 7. Administration of anticonvulsant, antidepressant, barbiturate, anxiolytic, or muscle relaxant drugs for more than one week prior screening. 8. History of alcohol or drug abuse. 9. Frequent episodes of nausea, dyspepsia, pain in the epigastric region, diarrhea, face and extremities edema, dizziness and headache. 10. History of any disease that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the subject during participation in the study 11. Clinically significant renal disorders.

-

Locations and Contacts

FGBU "State NII of Rheumatology" of RAMS, Moscow, Russian Federation
Additional Information

Starting date: July 2010
Last updated: November 15, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017